Literature DB >> 19375628

Overview of antifungal agents.

George R Thompson1, Jose Cadena, Thomas F Patterson.   

Abstract

This article is a comprehensive clinically focused review of currently available antifungals administered by way of the intravenous or inhalational route: amphotericin B and its lipid formulations, fluconazole, itraconazole, posaconazole, voriconazole, caspofungin, micafungin, anidulafungin, and flucytosine. Emphasis is placed on pharmacodynamics and kinetics, drug interactions, adverse events, and evidence for their use. Selected clinical trials demonstrating the efficacy of these agents are also reviewed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19375628     DOI: 10.1016/j.ccm.2009.02.001

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  27 in total

Review 1.  Clinical Guidance for Managing Statin and Antimicrobial Drug-Drug Interactions.

Authors:  Leigh Anne Hylton Gravatt; Rachel W Flurie; Estela Lajthia; Dave L Dixon
Journal:  Curr Atheroscler Rep       Date:  2017-10-09       Impact factor: 5.113

2.  Amphotericin B-impregnated bone cement to treat refractory coccidioidal osteomyelitis.

Authors:  Elizabeth S Zhu; George R Thompson; Christopher Kreulen; Eric Giza
Journal:  Antimicrob Agents Chemother       Date:  2013-09-03       Impact factor: 5.191

3.  Antifungal drug testing by combining minimal inhibitory concentration testing with target identification by gas chromatography-mass spectrometry.

Authors:  Christoph Müller; Ulrike Binder; Franz Bracher; Martin Giera
Journal:  Nat Protoc       Date:  2017-04-06       Impact factor: 13.491

Review 4.  Antifungal therapy in children: an update.

Authors:  Valerio Cecinati; Chiara Guastadisegni; Fabio Giovanni Russo; Letizia Pomponia Brescia
Journal:  Eur J Pediatr       Date:  2012-06-01       Impact factor: 3.183

5.  Toxicity mechanisms of amphotericin B and its neutralization by conjugation with arabinogalactan.

Authors:  Sarah Kagan; Diana Ickowicz; Miriam Shmuel; Yoram Altschuler; Edward Sionov; Miriam Pitusi; Aryeh Weiss; Shimon Farber; Abraham J Domb; Itzhack Polacheck
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

6.  Antifungal agents in current pediatric practice.

Authors:  Cecinati Valerio; Teresa Perillo; Letizia Brescia; Fabio Giovanni Russo
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725

7.  Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.

Authors:  Paul A Mann; Paul M McNicholas; Andrew S Chau; Reena Patel; Cara Mendrick; Andrew J Ullmann; Oliver A Cornely; Hernando Patino; Todd A Black
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

8.  Crystal structures of Trypanosoma brucei sterol 14alpha-demethylase and implications for selective treatment of human infections.

Authors:  Galina I Lepesheva; Hee-Won Park; Tatiana Y Hargrove; Benoit Vanhollebeke; Zdzislaw Wawrzak; Joel M Harp; Munirathinam Sundaramoorthy; W David Nes; Etienne Pays; Minu Chaudhuri; Fernando Villalta; Michael R Waterman
Journal:  J Biol Chem       Date:  2009-11-18       Impact factor: 5.157

9.  The interaction of aurein 2.5 with fungal membranes.

Authors:  Sarah R Dennison; Leslie H G Morton; Frederick Harris; David A Phoenix
Journal:  Eur Biophys J       Date:  2014-04-13       Impact factor: 1.733

10.  The dual role of candida glabrata drug:H+ antiporter CgAqr1 (ORF CAGL0J09944g) in antifungal drug and acetic acid resistance.

Authors:  Catarina Costa; André Henriques; Carla Pires; Joana Nunes; Michiyo Ohno; Hiroji Chibana; Isabel Sá-Correia; Miguel C Teixeira
Journal:  Front Microbiol       Date:  2013-06-26       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.